Trial · NCT03283371
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | -0.43 | Standard Error 0.162 | log(seizure/28 days) | |
| Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | -0.58 | Standard Error 0.165 | log(seizure/28 days) | |
| Percentage of Responders During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | 17.6 | percentage of responders | ||
| Percentage of Responders During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | 31.3 | percentage of responders | ||
| Number of Participants Free From Seizures During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | 1 | Participants | ||
| Number of Participants Free From Seizures During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | 0 | Participants | ||
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | Baseline | 16.23 | Standard Deviation 7.347 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | Baseline | 17.54 | Standard Deviation 7.223 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | Week 8 | 4.33 | Standard Deviation 50.740 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | Week 8 | 39.23 | Standard Deviation 130.988 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | Week 12 | 2.41 | Standard Deviation 52.613 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | Week 12 | 32.59 | Standard Deviation 104.775 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | Week 16 | -0.40 | Standard Deviation 43.380 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | Week 16 | 44.04 | Standard Deviation 153.714 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | Week 20 | 18.48 | Standard Deviation 101.318 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | Week 20 | 40.44 | Standard Deviation 144.768 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | Week 24 | 4.27 | Standard Deviation 47.125 | percent change |
| Percent Change From Baseline of Seizure-Free Days Change During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | Week 24 | 33.92 | Standard Deviation 114.436 | percent change |
| Percentage of Participants With Inadequate Treatment Response During Weeks 8 to 24 of Treatment | Placebo (Placebo-controlled Phase) | 6 | percentage of participants | ||
| Percentage of Participants With Inadequate Treatment Response During Weeks 8 to 24 of Treatment | Natalizumab 300 mg (Placebo-controlled Phase) | 3 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03283371/results